五点讲清！爆火的司美格鲁肽和替尔泊肽到底有什么区别？

Core Viewpoint - Semaglutide and Tirzepatide are two commonly used GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity, each with distinct structural and functional differences [2]. Mechanism of Action - Semaglutide stimulates insulin secretion from pancreatic beta cells, enhances glucose metabolism, and suppresses glucagon secretion, leading to reduced fasting and postprandial blood glucose levels [3]. - In contrast, Tirzepatide acts as a dual agonist for GLP-1 and GIP, activating GLP-1 receptors while mimicking natural GIP, with a weaker ability to drive GLP-1 receptor internalization compared to Semaglutide [5]. Clinical Efficacy - In clinical studies, Semaglutide demonstrated significant weight loss, with an average reduction of 14.9% after 68 weeks at a dose of 2.4 mg in the STEP 1 trial [6]. - Tirzepatide showed even stronger weight loss effects in the SURMOUNT-1 and SURMOUNT-2 phase III trials, with the highest dose of 15 mg resulting in an average weight loss of 20.9%, approximately 22 kg [6]. Side Effects - Both medications can cause similar gastrointestinal side effects, including nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and dyspepsia, typically mild to moderate and occurring early in treatment [7]. - However, Tirzepatide may reduce these side effects due to its action on GIP receptors, leading to fewer reported side effects and a stronger sense of satiety [9]. Approved Indications - Semaglutide is approved for the treatment of type 2 diabetes and obesity, including for adolescents aged 12 and older [10]. - Tirzepatide has been approved in China for weight management in patients with a BMI of ≥28 kg/m² or those with a BMI of 24-28 kg/m² with at least one comorbidity [10][11]. Administration Method - Both Semaglutide and Tirzepatide are administered via subcutaneous injection once a week, with Semaglutide also available in an oral tablet form (Rybelsus) for patients who prefer not to inject [12]. Conclusion - In summary, Semaglutide and Tirzepatide have distinct characteristics in terms of weight loss efficacy, mechanisms, side effects, and approved indications, and patients should choose the most suitable treatment based on their health status and medical advice [14].